ZA201500408B - Camsylate salt - Google Patents

Camsylate salt

Info

Publication number
ZA201500408B
ZA201500408B ZA2015/00408A ZA201500408A ZA201500408B ZA 201500408 B ZA201500408 B ZA 201500408B ZA 2015/00408 A ZA2015/00408 A ZA 2015/00408A ZA 201500408 A ZA201500408 A ZA 201500408A ZA 201500408 B ZA201500408 B ZA 201500408B
Authority
ZA
South Africa
Prior art keywords
camsylate salt
camsylate
salt
Prior art date
Application number
ZA2015/00408A
Other languages
English (en)
Inventor
Craig Robert Stewart
Martin Hans Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA201500408B publication Critical patent/ZA201500408B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ZA2015/00408A 2012-06-21 2015-01-20 Camsylate salt ZA201500408B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Publications (1)

Publication Number Publication Date
ZA201500408B true ZA201500408B (en) 2016-10-26

Family

ID=48746084

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00408A ZA201500408B (en) 2012-06-21 2015-01-20 Camsylate salt

Country Status (42)

Country Link
US (1) US10548882B2 (enExample)
EP (2) EP3064494A1 (enExample)
JP (2) JP2015520221A (enExample)
KR (1) KR102123708B1 (enExample)
CN (2) CN106279102A (enExample)
AP (2) AP2017009693A0 (enExample)
AR (2) AR091495A1 (enExample)
AU (2) AU2013279109B2 (enExample)
BR (2) BR112014031531B1 (enExample)
CA (1) CA2875589C (enExample)
CL (1) CL2014003374A1 (enExample)
CO (1) CO7151486A2 (enExample)
CR (2) CR20140571A (enExample)
CY (1) CY1119505T1 (enExample)
DK (1) DK2864316T3 (enExample)
DO (1) DOP2014000268A (enExample)
EC (1) ECSP14032215A (enExample)
ES (1) ES2618939T3 (enExample)
HR (1) HRP20170359T1 (enExample)
HU (1) HUE033376T2 (enExample)
IL (1) IL236131A0 (enExample)
IN (1) IN2014DN10088A (enExample)
LT (1) LT2864316T (enExample)
MA (2) MA39259B1 (enExample)
ME (1) ME02633B (enExample)
MX (1) MX354214B (enExample)
NI (1) NI201400146A (enExample)
NZ (2) NZ702742A (enExample)
PE (1) PE20150670A1 (enExample)
PH (2) PH12014502803A1 (enExample)
PL (1) PL2864316T3 (enExample)
PT (1) PT2864316T (enExample)
RS (1) RS55815B1 (enExample)
RU (1) RU2638175C2 (enExample)
SG (1) SG11201407934UA (enExample)
SI (1) SI2864316T1 (enExample)
SM (1) SMT201700142T1 (enExample)
TN (1) TN2014000491A1 (enExample)
TW (2) TWI639591B (enExample)
UA (1) UA114196C2 (enExample)
WO (1) WO2013190302A1 (enExample)
ZA (1) ZA201500408B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
AR107783A1 (es) 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
US20190262327A1 (en) * 2016-03-15 2019-08-29 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
CA3131753A1 (en) * 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat for weight loss

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP4273406B2 (ja) 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1729771B1 (en) 2004-03-22 2009-10-14 Eli Lilly & Company Pyridyl derivatives and their use as mglu5 receptor antagonists
RU2008100165A (ru) 2005-06-14 2009-07-20 Шеринг Корпорейшн (US) Ингибиторы аспартильных протеаз
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
WO2007076247A1 (en) 2005-12-21 2007-07-05 Boehringer Ingelheim International Gmbh Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
RU2009100074A (ru) 2006-06-12 2010-07-20 Шеринг Корпорейшн (US) Гетероциклические ингибиторы аспартильной протеазы
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
US20090325993A1 (en) 2007-02-01 2009-12-31 Nadia Mamoona Ahmad GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
WO2009100169A1 (en) 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EA201100461A1 (ru) 2008-09-11 2011-10-31 Амген Инк. Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
CN102348698B (zh) 2009-03-13 2015-06-03 生命医药公司 β-分泌酶的抑制剂
UY32751A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
TW201103893A (en) 2009-07-02 2011-02-01 Astrazeneca Ab New compounds
WO2011106414A1 (en) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
WO2011123674A1 (en) 2010-03-31 2011-10-06 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
UY33627A (es) 2010-09-24 2013-04-30 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors

Also Published As

Publication number Publication date
ES2618939T3 (es) 2017-06-22
PE20150670A1 (es) 2015-06-03
MA37666B1 (fr) 2016-12-30
CO7151486A2 (es) 2014-12-29
JP2015520221A (ja) 2015-07-16
PH12014502803B1 (en) 2015-02-23
DOP2014000268A (es) 2015-04-15
MA39259A1 (fr) 2017-12-29
RU2638175C2 (ru) 2017-12-12
EP2864316A1 (en) 2015-04-29
HK1206349A1 (en) 2016-01-08
AP2014008137A0 (en) 2014-12-31
PL2864316T3 (pl) 2017-09-29
TW201730177A (zh) 2017-09-01
CY1119505T1 (el) 2018-03-07
BR112014031531B1 (pt) 2022-08-02
AR105176A2 (es) 2017-09-13
AU2013279109B2 (en) 2017-08-31
BR122016014302A2 (pt) 2019-08-27
TWI639591B (zh) 2018-11-01
JP6509393B2 (ja) 2019-05-08
NZ727045A (en) 2018-06-29
WO2013190302A1 (en) 2013-12-27
US20140031379A1 (en) 2014-01-30
AR091495A1 (es) 2015-02-11
TWI588140B (zh) 2017-06-21
EP3064494A1 (en) 2016-09-07
AU2017254965A1 (en) 2017-11-23
TN2014000491A1 (en) 2016-03-30
SI2864316T1 (sl) 2017-04-26
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
SG11201407934UA (en) 2015-01-29
HRP20170359T1 (hr) 2017-05-05
BR122016014302B1 (pt) 2022-08-23
MA37666A1 (fr) 2016-04-29
IL236131A0 (en) 2015-02-01
ECSP14032215A (es) 2015-12-31
PH12014502803A1 (en) 2015-02-23
AU2017254965B2 (en) 2019-05-09
NI201400146A (es) 2016-09-21
LT2864316T (lt) 2017-03-27
MA39259B1 (fr) 2018-09-28
US10548882B2 (en) 2020-02-04
SMT201700142T1 (it) 2017-05-08
CR20140571A (es) 2015-02-04
KR102123708B1 (ko) 2020-06-16
MX2014014709A (es) 2015-03-04
CR20160202A (es) 2016-07-26
IN2014DN10088A (enExample) 2015-08-21
CN104411697A (zh) 2015-03-11
AP2017009693A0 (en) 2017-01-31
MX354214B (es) 2018-02-19
CL2014003374A1 (es) 2015-02-27
RS55815B1 (sr) 2017-08-31
RU2014148305A (ru) 2016-08-10
CN106279102A (zh) 2017-01-04
CN104411697B (zh) 2016-08-10
ME02633B (me) 2017-06-20
NZ702742A (en) 2016-12-23
KR20150023388A (ko) 2015-03-05
BR112014031531A2 (pt) 2017-06-27
DK2864316T3 (en) 2017-03-20
EP2864316B1 (en) 2016-12-14
UA114196C2 (uk) 2017-05-10
PT2864316T (pt) 2017-02-24
CA2875589C (en) 2020-08-25
HUE033376T2 (en) 2017-11-28
JP2018104448A (ja) 2018-07-05
PH12016500498A1 (en) 2017-04-10
TW201406745A (zh) 2014-02-16

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
AP2014007810A0 (en) Imidazopyrrolidinone compounds
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201215357D0 (en) Compounds
GB201214750D0 (en) Compounds
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
ZA201500408B (en) Camsylate salt
GB201204125D0 (en) Compounds
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
GB201209096D0 (en) Compounds
HUE036428T2 (hu) Sóhelyettesítõ
GB201219820D0 (en) Compounds
IL239281A0 (en) Dihydrochloride salt of cubicistat
GB201217310D0 (en) Compounds
PL2760822T3 (pl) Sole desfezoterodyny
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218758D0 (en) Compounds
GB201218774D0 (en) Compounds